Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

J. Cuzick; D. M. Berney; G. Fisher; D. Mesher; H. Moller; J. E. Reid; M. Perry; J. Park; A. Younus; A. Gutin; C. S. Foster; P. Scardino; J. S. Lanchbury; S. Stone

doi:10.1038/bjc.2012.39

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

J. Cuzick, D. M. Berney, G. Fisher, D. Mesher, H. Moller, J. E. Reid, M. Perry, J. Park, A. Younus, A. Gutin, C. S. Foster, P. Scardino, J. S. Lanchbury, S. Stone

Research output: Contribution to journal › Article › peer-review

314 Citations (Scopus)

Abstract

BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. METHODS: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. RESULTS: In univariate analysis (n = 349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P

Original language	English
Pages (from-to)	1095 - 1099
Number of pages	5
Journal	BJC: British Journal of Cancer
Volume	106
Issue number	6
DOIs	https://doi.org/10.1038/bjc.2012.39
Publication status	Published - 13 Mar 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2012.39

Cite this

Cuzick, J., Berney, D. M., Fisher, G., Mesher, D., Moller, H., Reid, J. E., Perry, M., Park, J., Younus, A., Gutin, A., Foster, C. S., Scardino, P., Lanchbury, J. S., & Stone, S. (2012). Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. BJC: British Journal of Cancer, 106(6), 1095 - 1099. https://doi.org/10.1038/bjc.2012.39

@article{21e280e6f56d402daf6b3df7df271e2d,

title = "Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort",

abstract = "BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. METHODS: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. RESULTS: In univariate analysis (n = 349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P",

author = "J. Cuzick and Berney, {D. M.} and G. Fisher and D. Mesher and H. Moller and Reid, {J. E.} and M. Perry and J. Park and A. Younus and A. Gutin and Foster, {C. S.} and P. Scardino and Lanchbury, {J. S.} and S. Stone",

year = "2012",

month = mar,

day = "13",

doi = "10.1038/bjc.2012.39",

language = "English",

volume = "106",

pages = "1095 -- 1099",

journal = "BJC: British Journal of Cancer",

issn = "1532-1827",

publisher = "Nature Publishing Group",

number = "6",

}

Cuzick, J, Berney, DM, Fisher, G, Mesher, D, Moller, H, Reid, JE, Perry, M, Park, J, Younus, A, Gutin, A, Foster, CS, Scardino, P, Lanchbury, JS & Stone, S 2012, 'Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort', BJC: British Journal of Cancer, vol. 106, no. 6, pp. 1095 - 1099. https://doi.org/10.1038/bjc.2012.39

TY - JOUR

T1 - Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

AU - Cuzick, J.

AU - Berney, D. M.

AU - Fisher, G.

AU - Mesher, D.

AU - Moller, H.

AU - Reid, J. E.

AU - Perry, M.

AU - Park, J.

AU - Younus, A.

AU - Gutin, A.

AU - Foster, C. S.

AU - Scardino, P.

AU - Lanchbury, J. S.

AU - Stone, S.

PY - 2012/3/13

Y1 - 2012/3/13

N2 - BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. METHODS: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. RESULTS: In univariate analysis (n = 349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P

AB - BACKGROUND: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. METHODS: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. RESULTS: In univariate analysis (n = 349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P

U2 - 10.1038/bjc.2012.39

DO - 10.1038/bjc.2012.39

M3 - Article

SN - 1532-1827

VL - 106

SP - 1095

EP - 1099

JO - BJC: British Journal of Cancer

JF - BJC: British Journal of Cancer

IS - 6

ER -

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this